This wiki has undergone a migration to Confluence found Here
CG WG Call Notes leading to 2015 January WGM
Jump to navigation
Jump to search
October 7, 2014 -- Weekly call
Proposed Agenda
- Consolidate the CG DIM and Clinical Sequencing DAM into a single CG DAM
- Best is to refocus our frozen project no. 705 "HL7 CG-omics Domain Analysis Model" to be CG DAM or deprecate the three DIM/DAM projects and start a new DAM project
- IOM data mapping
- Grant's proposal: "The record stored in the EHR should not be test-based, especially for large gene panels and whole exome/genome testing. Rather, it should be based on specific disease and medication assessment"; Scott's addition: "what about age based panels?"
- Amnon: should keep data aligned with the 'clinical genomics statement' (CGS) structure that include all the above components and dictate certain starting point; then, in human readable reports or in a summary layer of the EHR, it should be possible to analyse CGS instances relating to an individual, and show significance to a certain disease, medication, care goal/plan, etc.
- Larry's response: "first represent the list of data elements in an object model form so that we all can see the relationships, cardinality, constraints and other hidden qualities that are not evident in the list form"; "It would also require us to agree on precise definitions of the data elements and the context in which they are intended to be used"
- Amnon: I believe that the "object model" Larry is proposing to develop is the Clinical Genomics DIM (standards-independent)
- Grant: " The IOM would like to have an agreement by the Action Collaborative members on a solution by December, so that a pilot can be planned. All they want from us is to demonstrate by December that HL7 can provide the final standard. So a DSTU for the pilot is all we need."
- Amnon: We could upgrade one or more of our specifications to be aligned with the CG DIM and advance them to DSTU (if not already in this status)
- Grant's proposal: "The record stored in the EHR should not be test-based, especially for large gene panels and whole exome/genome testing. Rather, it should be based on specific disease and medication assessment"; Scott's addition: "what about age based panels?"
Attendees
- Amnon Shabo (Shvo),